As single agent, the use of PI3K inhibitors for the treatment of a variety of cancers have thus far demonstrated limited efficacy, probably because there is not enough drug to have a significant biological activity and to observe a significant therapeutic response at the doses currently employed. Here, PIK3CD is linked to cancer.